Company profile: Beacon Biomedical
1.1 - Company Overview
Company description
- Provider of easy, accurate, and affordable blood-based tests for earlier cancer detection, developing and commercializing waived test (LDT) solutions for healthcare practitioners and individuals. Offerings include BeScreened-CRC, a blood-based colorectal cancer screening test for adults 45+ who are unwilling or unable to undergo traditional screening methods.
Products and services
- Waived Early Cancer Detection Tests: Waived assays deliver easy, accurate and affordable blood testing to screen for cancers earlier for healthcare practitioners and individuals who need accessible diagnostics
- BeScreened-CRC: Blood-based colorectal cancer screening test engineered for individuals 45 years or older unwilling or unable to undergo traditional screening methods, offering earlier detection with easy, accurate and affordable performance
- Laboratory-Developed Test (LDT) Systems: LDT blood tests are developed and commercialized for healthcare practitioners and individuals to enable earlier cancer detection with accessible and accurate assays
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Beacon Biomedical
MDxHealth
HQ: United States
Website
- Description: Provider of molecular diagnostics and epigenetic tests for cancer assessment and personalized treatment, including Select mdx (urine test to identify men at risk for aggressive prostate cancer before an initial biopsy), Confirm mdx (tissue test for risk of undetected clinically significant prostate cancer after a negative biopsy), Genomic Prostate Score (predicts disease aggressiveness), and Resolve mdx (PCR UTI test with personalized antibiotic options).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MDxHealth company profile →
GPC Biotech
HQ: Germany
Website
- Description: Provider of anticancer drug discovery and development as a German biopharmaceutical company. Portfolio includes Satraplatin, a platinum-based small molecule for prostate cancer; MAb 1D09C3, a monoclonal antibody for lymphoma; and RGB-286199, a small molecule for refractory cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GPC Biotech company profile →
Mirati Therapeutics
HQ: Canada
Website
- Description: Provider of novel cancer therapeutics in clinical development and commercialization; product candidates include MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirati Therapeutics company profile →
RefleXion
HQ: United States
Website
- Description: Provider of biologically-guided radiotherapy systems for patients with cancer, offering SCINTIX therapy that uses emissions from cancer cells to target and treat lung or bone tumors at any stage. Provides the RefleXion X1 platform delivering SCINTIX and CT-guided IMRT and SBRT with fan-beam kVCT imaging for superior patient localization, plus Limbus Contour integration to expedite radiotherapy planning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RefleXion company profile →
VelosBio
HQ: United States
Website
- Description: Provider of clinical-stage, next-generation oncology therapeutics, developing first-in-class ROR1-directed treatments, including novel antibody-drug conjugates for hematologic and solid tumors; offerings include injection-based therapies such as WINREVAIR (sotatercept-csrk) and KEYTRUDA (pembrolizumab).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VelosBio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Beacon Biomedical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Beacon Biomedical
2.2 - Growth funds investing in similar companies to Beacon Biomedical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Beacon Biomedical
4.2 - Public trading comparable groups for Beacon Biomedical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →